Recursion Expands Collaborations and Advances Precision Oncology with Tempus, NVIDIA, and Bayer
Recursion, a clinical stage TechBio company, has announced significant updates to its collaborations with Tempus, NVIDIA, and Bayer, furthering its ambitions in the precision oncology space. The collaboration with Tempus provides Recursion with access to a vast proprietary oncology dataset, enabling the discovery of potential biomarker-enriched therapeutics at scale. Recursion is expanding its BioHive-1 supercomputer, powered by NVIDIA, to increase its computational capacity and accelerate the impact of its accumulated data. Additionally, Recursion has updated its collaboration with Bayer for precision oncology programs, potentially leading to innovative cancer therapies. These collaborations highlight Recursion's commitment to leveraging data, advanced computing power, and strategic partnerships to advance drug discovery and improve patient outcomes in oncology.
Collaboration with Tempus for Precision Oncology Data
Recursion has entered into an agreement with Tempus, granting preferred access to a large proprietary oncology dataset. This dataset includes de-identified patient-centric information such as DNA, RNA, and health records. By combining Tempus' forward genetics approach with Recursion's reverse genetics approach, the collaboration aims to enhance the speed, precision, and scale of therapeutic development in oncology. Recursion will pay Tempus up to $160 million over the next five years for continued access to this valuable dataset.
Expanding Supercomputing Power with NVIDIA
To harness the potential of its accumulated data, Recursion is expanding its BioHive-1 supercomputer. By adding over 500 NVIDIA H100 Tensor Core GPUs to the existing 300 NVIDIA A100 Tensor Core GPUs, Recursion aims to quadruple its computational capacity. This enhanced computing power will support the company's pipeline, partnerships, and the construction of large-scale AI models across multiple modalities of biology and chemistry. The expanded BioHive-1 is expected to rank among the top 50 most powerful supercomputers globally, making it the most powerful supercomputer owned by a biopharma company.
Updated Collaboration with Bayer for Precision Oncology Programs
Recursion has also updated its collaboration with Bayer, focusing on precision oncology programs. The partnership allows Bayer to leverage Recursion's capabilities in identifying novel targets and chemistry for oncology indications. Under the agreement, up to seven oncology programs may be initiated, with potential future payments to Recursion totaling up to $1.5 billion, along with royalties on net sales.
In conclusion, Recursion's collaborations with Tempus, NVIDIA, and Bayer demonstrate the company's commitment to leveraging data, advanced computing power, and strategic partnerships to advance precision oncology. By accessing vast datasets, expanding supercomputing capabilities, and partnering with industry leaders, Recursion aims to drive innovation and improve patient outcomes in the field of oncology.
Implications of Recursion's Expanding Collaborations for New Businesses
For new businesses in the biotech and healthcare sectors, Recursion's expanding collaborations with Tempus, NVIDIA, and Bayer offer valuable insights. Recursion's approach to precision oncology, leveraging vast datasets, advanced computing power, and strategic partnerships, sets a benchmark for innovation and improved patient outcomes.
Accessing Proprietary Oncology Data
New businesses can learn from Recursion's agreement with Tempus, which provides access to a large proprietary oncology dataset. This collaboration underscores the importance of data in accelerating the discovery and development of therapeutics.
Investing in Advanced Computing Power
Recursion's expansion of its BioHive-1 supercomputer, powered by NVIDIA, illustrates the critical role of computational capacity in harnessing the potential of accumulated data. For new businesses, this highlights the value of investing in advanced computing capabilities to support their pipelines and partnerships.
Strategic Partnerships for Precision Oncology
Recursion's updated collaboration with Bayer emphasizes the significance of strategic partnerships in advancing precision oncology. New businesses can benefit from forming partnerships that allow them to leverage each other's capabilities in identifying novel targets and chemistry for specific indications.
In conclusion, Recursion's expanding collaborations offer a roadmap for new businesses in the biotech and healthcare sectors. By leveraging data, investing in advanced computing power, and forming strategic partnerships, new businesses can drive innovation and improve patient outcomes in their respective fields.
.svg)
